Articles tagged with Vaccine Development
Researchers found that Th17 cells protect against the Trypanosoma cruzi parasite, which causes Chagas disease, by activating the immune system. This discovery offers a new approach to developing more protective vaccines for these diseases.
Scientists have identified thousands of previously unknown epitopes on the surface of cells, which could lead to a deeper understanding of the immune system and new avenues for therapies. The discovery of 'spliced' epitopes could provide new targets for immunotherapy and vaccine design.
A new study by Michigan State University researchers demonstrates that digital scans of a young child's fingerprint can be correctly recognized one year later, allowing for proper medical care. The technique has the potential to save millions of lives by tracking vaccination records and providing lifelong identity.
Researchers from UTMB have developed three new potential vaccines against the plague that protect animals from developing pneumonic plague as late as four to five months after vaccination. The vaccines were engineered by deleting and modifying genes in Yersinia pestis bacteria, resulting in safe vaccine candidates.
Researchers used satellite imagery and vaccination records to estimate population size and optimize vaccination coverage. The study showed that timing vaccination campaigns with predictable population peaks can improve coverage, especially in areas with limited access to health services.
IDRI aims to develop a safe and effective Zika vaccine using RNA-based technology, which can be rapidly manufactured without requiring egg growth or bacteria cultivation. The institute plans to leverage the Zika virus's own machinery for expression of immunogenic proteins.
Researchers at the University of Pittsburgh School of Medicine have developed two successful Zika vaccines that protect against neurological damage in newborn mice. The microneedle array vaccine showed significant protection, while the adenovirus-based vaccine was used as a proof-of-principle vaccine to test the envelope protein antigen.
Researchers have developed a new approach to creating human vaccines against HIV using Kymouse, a genetically modified mouse that mimics human antibody responses. The study found that Kymouse can produce antibodies of the type needed for protection, suggesting ways to improve immunization regimes.
Researchers have successfully developed new approaches to induce HIV-blocking antibodies in mice with human-like immune systems. The studies showed that a prime shot combined with booster shots of immunogens can activate precursor cells to produce neutralizing antibodies, paving the way for future clinical studies.
Researchers find that a widely available dengue vaccine could worsen the disease in some settings, particularly in low-transmission areas. The vaccine has shown to reduce illness and hospitalization by 20-30% in high-transmission countries but may increase these rates in locations with lower transmission.
A novel schistosomiasis vaccine called Sm14 Vaccine has reached phase II clinical studies, prioritized by the World Health Organization. The vaccine aims to prevent the parasite that causes the disease from installing in the patient's organism and causing damage.
Researchers cloned an epidemic strain of Zika virus, creating a model to test strategies for stopping the pandemic. The clone is used for developing a live but attenuated vaccine to create long-term immunity.
Two vaccine candidates have shown complete protection against the Zika virus in rhesus monkeys, with no adverse effects observed. The findings, published in the journal Science, provide a promising lead for developing a safe and effective human vaccine to combat this mosquito-borne disease.
Researchers have successfully tested two Zika vaccine candidates in nonhuman primates, demonstrating robust protection against both Brazilian and Puerto Rican strains of the virus. The findings support the advancement of these vaccine candidates to human trials, with phase 1 clinical testing expected to begin later this year.
Three different investigational Zika virus vaccine platforms protect against infection and induce immune responses in rhesus macaques. The results suggest that each approach holds promise for designing an effective Zika vaccine.
Researchers at Duke University Medical Center have discovered key immune differences that can help in the development of an effective HIV vaccine. The study found that HIV-infected individuals with broadly neutralizing antibodies had similar immune alterations as those with autoimmune disease.
The National Institute of Allergy and Infectious Diseases (NIAID) has begun a Phase 1 study to evaluate the safety and efficacy of an experimental yellow fever vaccine developed by Bavarian Nordic. The trial will assess whether the investigational vaccine can prevent yellow fever virus infection and induce a strong immune response.
Researchers have identified specific antibodies that protect against Zika infection in mice, targeting a region of the virus similar to other flaviviruses like Dengue and West Nile. These findings aim to optimize current vaccine strategies and develop new antibody-based therapeutics.
Researchers at McMaster University have developed a novel vaccine candidate, BD584, which shows promise in reducing chlamydial shedding and hydrosalpinx by 95% and 87.5%, respectively. The vaccine has the potential to be widely protective against all Chlamydia trachomatis strains, including those causing trachoma.
A new minimally invasive tissue sampling technique will help determine the cause of death in children, facilitating ways to save lives and improve health in vulnerable areas. The CHAMPS project aims to create a network of disease surveillance sites to address child mortality rates, which claim nearly 6 million lives annually.
A new preclinical study suggests that an effective Zika vaccine is achievable. Two vaccine candidates were tested and found to be safe and protective against the virus in mice. The purified inactivated virus (PIV) vaccine is being developed and planned for human testing later this year.
A new study published in Nature demonstrates complete protection against the Zika virus in mice using two different vaccine candidates. The researchers showed that a single dose of either a DNA vaccine or a purified inactivated virus vaccine provides complete protection, similar to existing vaccines for other flaviviruses.
A new software tool, RepeatAnalyzer, has been developed to track and catalogue short repeating sequences of bacterial DNA, improving scientists' ability to identify and understand bacterial strains. This technology could significantly accelerate vaccine development for tick-borne bacteria such as Anaplasma marginale.
Researchers at Vanderbilt University Medical Center are recruiting volunteers for a clinical trial aimed at decoding the human immunome. The study, part of the Human Vaccines Project, will generate data on the genetic underpinnings of the immune system to guide next-generation vaccine development.
Using drones to deliver vaccines in low- and middle-income countries could improve vaccination rates by up to 96% while producing significant cost savings. The technology has the potential to save $8.93 per dose and annual infrastructure costs of up to $60,000.
Lomonosov Moscow State University scientists have developed a new method to extract DNA from various organisms. This breakthrough could lead to the creation of preventive vaccines against infectious diseases, allergies, and cancers.
Researchers genetically engineered a Zika virus infectious cDNA clone, enabling rapid vaccine development and exploration of the virus's evolution and transmission. The study unlocks insights into why the Zika virus causes severe diseases and epidemics.
Researchers have developed zinc-oxide nanoparticles that can prevent the herpes simplex virus from entering cells and stimulate natural immunity to develop. The particles, called ZOTEN, work by attracting the virus and allowing immune cells to process it.
Researchers at the University of Copenhagen have created a general and user-friendly platform for developing effective vaccines. The technique mimics the structure of a virus, allowing it to trigger an immune response against diseases such as cancer, asthma, and allergies.
Global norovirus experts identify key gaps in knowledge and provide information to further vaccine development. The most efficient approach is developing a vaccine for young children, with the greatest impact at the global level.
Experts argue that good governance, long-term technology investment, and strong product management skills are essential to combat infectious outbreaks. The proposed global strategy aims to pool funds and coordinate efforts to develop effective countermeasures for these diseases.
An immunization regimen using two Ebola vaccine candidates was found to be safe and well-tolerated, inducing an immune response in healthy adult volunteers. The study's results suggest that the vaccines could provide durable protection against Ebola, which is essential for areas with intermittent outbreaks.
A new malaria vaccine, RTS,S/AS01, has been developed to combat the disease. Despite waning efficacy in infants and young children, researchers argue that the vaccine could still be used in targeted strategies to interrupt transmission in low-endemic areas.
A preclinical study conducted by Texas Biomed has shown that Mymetics' HIV vaccine candidate generated significant protection in female monkeys, with an efficacy rate of 87%, delaying persistent infection after repeated viral challenges. The study's results suggest a potential breakthrough in developing an effective HIV vaccine.
A team of researchers from Purdue University has determined the structure of the Zika virus, revealing insights critical to developing effective antiviral treatments and vaccines. The study identified unique regions in the virus structure that could explain differences in transmission and disease manifestation.
A team of UCI scientists led by Philip Felgner has received $8 million to develop a new vaccine for Q fever, a highly infectious agent considered a potential bioterrorism weapon. The vaccine aims to mitigate severe side effects of the current vaccine and is expected to be safer and more effective.
Researchers at the University of Vermont and National Institutes of Health have developed a highly effective dengue vaccine requiring only one dose. The vaccine has shown promise in protecting against all four dengue strains, with no adverse reactions reported among test subjects.
A clinical trial showed that the experimental vaccine TV003 protected all 21 volunteers from infection, while placebo recipients developed infection. The study's results inform a phase 3 efficacy trial and offer new hope for dengue prevention.
Researchers found a promising single-dose dengue vaccine effective in preventing human volunteers from contracting the virus, protecting against infection. The study's findings could be the final piece in developing an effective vaccine against dengue, which infects nearly 400 million people annually.
A research team has identified rare potent antibodies in an HIV-infected individual and determined sequential structures that point to how they developed. This finding will help guide researchers as they try to build an experimental vaccine that recreates the pathway that gives rise to these important broadly neutralizing antibodies.
A new study suggests that Middle East Respiratory Syndrome coronavirus (MERS-CoV) develops mutations that make the virus less virulent during an outbreak, challenging current vaccine strategies. The study found two specific point mutations in the viral spike protein that impaired fitness and virulence.
Researchers tested a Plasmodium vivax malaria vaccine candidate in 30 volunteers and found that it significantly delayed parasitemia in 59% of vaccinated subjects. The study also identified limitations to primaquine treatment, highlighting the need for improved vaccines.
A new policy report in Science issues recommendations for responding to infectious disease epidemics, citing the Ebola crisis as a framework. The report proposes rebuilding local health care infrastructures and improving international response capabilities.
A European alliance, EHVA, has been granted 28 million Euros to develop novel preventive and therapeutic vaccines against HIV. The project aims to accelerate the development of innovative HIV vaccine concepts, focusing on prophylactic and therapeutic approaches.
BioMARC, a high-containment biopharmaceutical unit at CSU, has been awarded $4.6 million to develop and manufacture vaccines for three additional viruses causing severe long-term disease. The facility will produce vaccines using VRP technology, which works to better immunize individuals.
Scientists at the University of Oxford have created a new technique to speed up vaccine development, utilizing isopeptide bonds to assemble vaccine candidates. This approach enables rapid production of stable vaccines with robust antibody responses.
Researchers have filmed in vivo the process by which an AIDS vaccine candidate recruits immune cells to destroy infected cells. The study, published in Nature Medicine, shows how the vaccine induces the formation of the inflammasome, a complex assembly of proteins that triggers an immune response.
A US$200,000 grant from the Bill & Melinda Gates Foundation will support the development of a one-shot vaccine for tapeworms, reducing deaths from neurocysticercosis in developing countries. The vaccine aims to break the lifecycle of the parasite, causing brain cysts and seizures.
A £5.7 million grant from the Biotechnology and Biological Sciences Research Council (BBSRC) will support the development of cheap and effective vaccines for poultry. The project aims to reduce infections in humans and minimize antibiotics in the food chain, with potential applications for cattle, sheep, and goats.
A no-fault vaccine injury compensation fund is proposed to address liability concerns and ensure recipients are fairly compensated in rare cases of harm. The World Bank could oversee the program, which would provide rapid deployment of vaccines without hesitation due to liability concerns.
A team of researchers at the University of Illinois has developed a novel computational approach to accelerate the search for a hepatitis C vaccine. By analyzing the fitness landscape of the virus, they identified optimal formulations targeting viral vulnerabilities that can be attacked by the immune system.
A Phase 2 clinical trial is underway to test a chikungunya vaccine in 400 healthy adult volunteers. The trial aims to assess the safety and immune response of the vaccine, which has shown promising results in previous studies.
A team of chemists led by Yan-Yeung Luk has created synthetic disaccharide derivatives (DSDs) that mimic and dominate the functions of rhamnolipid molecules produced by bacteria. The new molecules have been shown to control various activities, including biofilm formation and bacterial adhesion.
Researchers have identified specific immune cells that could be targeted by a new MRSA vaccine. These 'T-helper type 1' cells play a critical role in the immune response and are elevated in patients following MRSA infection. A model vaccine targeting these cells has shown improved infection outcomes.
Researchers have developed a new RSV vaccine candidate that has shown promising early results in young children, eliciting more antibodies than previous candidates. The vaccine uses a genetically engineered version of the virus with a deleted M2-2 protein to induce a stronger immune response.
Researchers at Osaka University have discovered a new role for p62 in the immune response to Toxoplasma gondii, paving the way for the development of an inactivated vaccine. The study found that p62 plays a crucial role in activating killer T cells in infected cells stimulated by interferon-γ.
Researchers at Duke Medicine have discovered that rhesus monkeys can transmit the virus across the placenta to their unborn offspring, establishing a first primate model to study mother-to-fetus CMV infections. The discovery aims to spur development of potential vaccine approaches against congenital CMV infections.
The Global Health Vaccine Center of Innovation (GHVCI) aims to accelerate vaccine development and make vaccines more accessible globally. The GHVCI combines IDRI's vaccine design technologies with Sanofi Pasteur's expertise in vaccine development, formulation, and production.
Researchers at Scripps Florida Institute have been awarded $6 million to develop an innovative HIV/AIDS vaccine that has shown promise in animal models. The approach works by blocking key sites on the virus's surface, preventing it from attaching and invading human immune cells.
A Phase 2a trial will assess the safety and immunogenicity of IDRI's TB vaccine candidate in 60 participants in South Africa, who have previously had active TB. The trial aims to reduce TB recurrence after treatment, a major threat to TB control programs.